Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
| SparkCures ID | 153 |
|---|---|
| Developed By | Genentech |
| Generic Name | Atezolizumab |
| Additional Names | MPDL3280A |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
There are no resources, links or videos to display for this treatment.